$KYNB earnings report

Kyntra Bio Q3 2026: net income of $157 thousand driven by a $14,011 thousand debt restructuring gain, while operating loss widened to $(12,865) thousand. AlphAI read Kyntra Bio's Q3 FY2026 filing as weak.

Q3 FY2026

AlphAI · Earnings readKYNB · Q3 2026 · ended 2026-09-30

Kyntra Bio Q3 2026: net income of $157 thousand driven by a $14,011 thousand debt restructuring gain, while operating loss widened to $(12,865) thousand

↓Weak quarter

Operating loss widened from $(5,411) thousand to $(12,865) thousand, with R&D rising from $1,209 thousand to $8,266 thousand. The quarter's net income depends on a $14,011 thousand gain on debt restructuring. Nine-month net loss is $(3,067) thousand against net income of $197,672 thousand in the prior-year period, which included discontinued operations. Cash, short-term investments and receivables total $44.1 million, with runway stated into 2028 and the Phase 3 start contingent on a partnership or external capital raise.

Revenue
$1.76M
Drug product revenue, net
$1,663 thousand (Q3 2026); $957 thousand (Q3 2025)
EPS · GAAP
$0.04

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, Q3 2026 (three months ended Sep 30, 2026)GAAP$1.76M––
Development and other revenue, Q3 2026GAAP$99K––
Drug product revenue, net, Q3 2026GAAP$1.66M––
Cost of goods sold, Q3 2026GAAP$619K––
Research and development, Q3 2026GAAP$8.27M––
Selling, general and administrative, Q3 2026GAAP$5.76M––
Restructuring charge, Q3 2026GAAP−$15K––
Total operating costs and expenses, Q3 2026GAAP$14.63M––
Loss from operations, Q3 2026GAAP−$12.87M––
Interest expense, Q3 2026GAAP−$1.63M––
Gain on debt restructuring, Q3 2026GAAP$14.01M––
Interest income and other income (expenses), net, Q3 2026GAAP$643K––
Total interest and other, net, Q3 2026GAAP$13.02M––
Income (loss) from continuing operations before income taxes, Q3 2026GAAP$157K––
Income (loss) from continuing operations, Q3 2026GAAP$157K––
Net income (loss), Q3 2026GAAP$157K––
Income (loss) from continuing operations per share, basic and diluted, Q3 2026GAAP$0.04––
Net income (loss) per share, basic and diluted, Q3 2026GAAP$0.04––
Total revenue, nine months ended Sep 30, 2026GAAP$4.03M––
Development and other revenue, nine months ended Sep 30, 2026GAAP$449K––
Drug product revenue, net, nine months ended Sep 30, 2026GAAP$3.58M––
Cost of goods sold, nine months ended Sep 30, 2026GAAP$4.73M––
Research and development, nine months ended Sep 30, 2026GAAP$22.65M––
Selling, general and administrative, nine months ended Sep 30, 2026GAAP$20.95M––
Restructuring charge, nine months ended Sep 30, 2026GAAP−$48K––
Total operating costs and expenses, nine months ended Sep 30, 2026GAAP$48.28M––
Loss from operations, nine months ended Sep 30, 2026GAAP−$44.26M––
Interest expense, nine months ended Sep 30, 2026GAAP−$6.43M––
Gain on deconsolidation of subsidiary, nine months ended Sep 30, 2026GAAP$30.94M––
Gain on debt restructuring, nine months ended Sep 30, 2026GAAP$14.01M––
Total interest and other, net, nine months ended Sep 30, 2026GAAP$41.26M––
Income (loss) from continuing operations before income taxes, nine months ended Sep 30, 2026GAAP−$3.00M––
Income (loss) from continuing operations, nine months ended Sep 30, 2026GAAP−$3.00M––
Income (loss) from discontinued operations, net of tax, nine months ended Sep 30, 2026GAAP−$66K––
Net income (loss), nine months ended Sep 30, 2026GAAP−$3.07M––
Income (loss) from continuing operations per share, basic and diluted, nine months ended Sep 30, 2026GAAP$(0.74)––
Net income (loss) per share, basic and diluted, nine months ended Sep 30, 2026GAAP$(0.76)––

Segments

SegmentRevenueq/qy/y
Drug product revenue, netThe filing prints the figure but gives no explanation for its change. The release describes that the Company recognizes roxadustat drug product revenue from Astellas in the Astellas territories excluding Japan, which is the basis for the royalty payment mechanism, not a stated driver of the quarter's revenue.$1,663 thousand (Q3 2026); $957 thousand (Q3 2025)––
Development and other revenueThe filing prints the figures but gives no explanation for the change.$99 thousand (Q3 2026); $119 thousand (Q3 2025)––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The filing reports a Q3 2026 gain on debt restructuring of $14,011 thousand and a nine-month gain on deconsolidation of subsidiary of $30,940 thousand. The company's amended royalty financing agreement with NQ Project Phoebus, L.P. reduces maximum aggregate payments from $125 million to $65 million, including a $42.6 million accelerated payment, and caps remaining payments at $15 million from 50% of roxadustat drug product revenue from Astellas in the Astellas territories excluding Japan.
  • The filing states the amendment returns NQ Project Phoebus, L.P.'s invested capital in full, with total payments made to date of $50 million.

What drove it

  • The release states that the FG-3246 and FG-3180 programs were discontinued after insufficient efficacy at the pre-specified Phase 2 interim analysis, with savings of over $20 million in operating expenses expected in 2027 and 2028.
  • The release states the royalty financing amendment is expected to materially reduce the Company's payment obligations, and reports a Q3 2026 gain on debt restructuring of $14,011 thousand.
  • The filing reports Q3 2026 R&D of $8,266 thousand against $1,209 thousand in Q3 2025, but gives no explanation for the increase in the financial statements.

Concerns

  • Loss from operations was $(12,865) thousand in Q3 2026 against $(5,411) thousand in Q3 2025. Net income for the quarter ($157 thousand) relies on the $14,011 thousand gain on debt restructuring, which is non-operating.
  • Cost of goods sold was $4,727 thousand for the nine months ended Sep 30, 2026, against $278 thousand in the prior-year period, while nine-month drug product revenue fell to $3,577 thousand from $4,767 thousand.
  • Total liabilities are $56,041 thousand against total assets of $48,851 thousand, and total deficit is $(28,670) thousand. Accrued and other liabilities rose to $31,005 thousand from $20,183 thousand at Dec 31, 2025.
  • The Phase 3 trial start is planned for 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise. The release does not state that either transaction has been agreed.
  • Cash, cash equivalents, investments and accounts receivable fell to $44.1 million at Sep 30, 2026. Cash and cash equivalents alone fell from $47,872 thousand to $9,905 thousand over the nine months.

What to watch

  • Whether the company executes a strategic partnership or an external capital raise to start the pivotal Phase 3 trial of roxadustat in LR-MDS patients with high transfusion burden in 1Q 2027.
  • Completion of the FG-3246 study close-out and realization of the more than $20 million in operating expense savings expected in 2027 and 2028.
  • Progress of the $15 million remaining royalty-backed payment cap, paid from 50% of roxadustat drug product revenue from Astellas in the Astellas territories excluding Japan, and the termination of the amended agreement once the cap is reached.
  • Trajectory of R&D and cash balances against the stated runway into 2028.
  • Q4 2026 results, which will show whether the discontinued programs' costs decline as the release expects.

Balance sheet and cash flow

  • Cash and cash equivalents: $9,905 thousand at Sep 30, 2026, versus $47,872 thousand at Dec 31, 2025.
  • Short-term investments: $30,385 thousand at Sep 30, 2026, versus $41,106 thousand at Dec 31, 2025.
  • Long-term investments: $0 (printed as a dash) at Sep 30, 2026, versus $20,160 thousand at Dec 31, 2025.
  • Accounts receivable, net: $3,848 thousand at Sep 30, 2026, versus $216 thousand at Dec 31, 2025.
  • The release states cash, cash equivalents, investments and accounts receivable of $44.1 million as of Sep 30, 2026, and expects them to be sufficient to fund operating plans into 2028.
  • Total assets: $48,851 thousand at Sep 30, 2026, versus $119,594 thousand at Dec 31, 2025.
  • Total liabilities: $56,041 thousand at Sep 30, 2026, versus $115,119 thousand at Dec 31, 2025.
  • Liability related to sale of future revenues, non-current: $11,268 thousand at Sep 30, 2026, versus $65,980 thousand at Dec 31, 2025.
  • Total deficit: $(28,670) thousand at Sep 30, 2026, versus $(17,005) thousand at Dec 31, 2025.
  • Total stockholders' deficit attributable to Kyntra Bio: $(29,190) thousand at Sep 30, 2026, versus $(30,038) thousand at Dec 31, 2025.
  • Operating cash flow, investing cash flow and free cash flow are not reported in the filing.

Analysis

Kyntra Bio reported Q3 2026 total revenue of $1,762 thousand, up from $1,076 thousand in Q3 2025, with drug product revenue, net of $1,663 thousand against $957 thousand. Development and other revenue was $99 thousand against $119 thousand. Revenue is small relative to operating costs, which were $14,627 thousand against $6,487 thousand a year earlier. Research and development rose to $8,266 thousand from $1,209 thousand, the largest single driver of the operating loss, which widened to $(12,865) thousand from $(5,411) thousand. SG&A was $5,757 thousand against $5,295 thousand. The filing does not explain the R&D increase in the financial statements.

The reported quarterly net income of $157 thousand, or $0.04 per basic and diluted share, reflects a $14,011 thousand gain on debt restructuring within total interest and other, net of $13,022 thousand. The prior-year Q3 comparison was a net income of $200,636 thousand, which included $213,782 thousand from discontinued operations. Income from continuing operations for Q3 2025 was a loss of $(13,146) thousand. The nine-month figures show a net loss of $(3,067) thousand, against net income of $197,672 thousand in the prior-year period. Nine-month cost of goods sold was $4,727 thousand against $278 thousand, and nine-month drug product revenue was $3,577 thousand against $4,767 thousand.

The balance sheet shows total assets of $48,851 thousand against $119,594 thousand at Dec 31, 2025, and a total deficit of $(28,670) thousand. Cash and cash equivalents fell to $9,905 thousand from $47,872 thousand, and the release states cash, investments and accounts receivable of $44.1 million, with runway into 2028. The liability related to sale of future revenues fell to $11,268 thousand from $65,980 thousand following the royalty financing amendment, which the release describes as returning NQ Project Phoebus, L.P.'s invested capital in full.

The release frames the quarter around a strategic reset: discontinuation of FG-3246 and FG-3180 after insufficient efficacy at the Phase 2 interim analysis, with savings of over $20 million in operating expenses expected in 2027 and 2028, and a pivotal Phase 3 roxadustat trial in LR-MDS planned for 1Q 2027 subject to a partnership or external capital raise. The filing gives no quantified guidance for revenue, margins or operating expenses, so no guidance comparison is made.

The figures that deserve the most attention are the operating loss, the R&D step-up, the non-operating gain that produced the quarter's net income, and the funding condition attached to the Phase 3 start. The release does not state gross margin, operating cash flow or a prior-quarter comparison, and these are listed as missing items.

Management, verbatim

Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,

Thane Wettig, Chief Executive Officer of Kyntra Bio

We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.

Thane Wettig, Chief Executive Officer of Kyntra Bio

Not in the filing

stated, not guessed
  • Gross margin is not printed in the filing.
  • Prior-quarter (Q2 2026) figures are not printed, so qoq_change and prior_quarter fields are null.
  • Year-over-year percentage changes are not printed for any line, so yoy_change fields are null.
  • The filing does not label the statements as GAAP; GAAP basis is assigned because these are the condensed consolidated statements of operations.
  • No non-GAAP measures or reconciliations are provided.
  • No quantified revenue, margin, operating expense or tax guidance is provided, so the guidance field is null.
  • Cash flow statement figures (operating, investing and financing cash flow) are not provided.
  • Share repurchase and dividend data are not provided.
  • The per-share income (loss) from discontinued operations for Q3 2026 is printed as a dash and is not reported as a figure.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about KYNB earnings dates

When is Kyntra Bio's next earnings date?
AlphAI has no date for KYNB yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.